USA - NASDAQ:NIVF - VGG0544E3032 - Common Stock
The current stock price of NIVF is 0.76 USD. In the past month the price decreased by -58.7%. In the past year, price decreased by -99.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.41 | 99.12B | ||
| CI | THE CIGNA GROUP | 8.6 | 65.24B | ||
| LH | LABCORP HOLDINGS INC | 16.05 | 21.10B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 200.69 | 19.55B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.03 | 19.67B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.35 | 15.75B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.60B | ||
| HIMS | HIMS & HERS HEALTH INC | 56.83 | 10.27B | ||
| DVA | DAVITA INC | 12.27 | 8.51B | ||
| CHE | CHEMED CORP | 19.6 | 6.28B | ||
| RDNT | RADNET INC | 211.08 | 5.85B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 60.09 | 5.85B |
NewGenIVF Group Ltd. operates as an assisted reproductive services provider. The company is headquartered in Bangkok, Bangkok Metropolis and currently employs 76 full-time employees. The company went IPO on 2022-02-15. The company specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. The company has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
NEWGENIVF GROUP LTD-A
13/F, Ps Tower, Sukhumvit 21 Rd (Asoke)
Bangkok BANGKOK METROPOLIS TH
Employees: 76
Phone: 6568185796
NewGenIVF Group Ltd. operates as an assisted reproductive services provider. The company is headquartered in Bangkok, Bangkok Metropolis and currently employs 76 full-time employees. The company went IPO on 2022-02-15. The company specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. The company has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
The current stock price of NIVF is 0.76 USD. The price decreased by -29.63% in the last trading session.
NIVF does not pay a dividend.
NIVF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
NIVF stock is listed on the Nasdaq exchange.
NEWGENIVF GROUP LTD-A (NIVF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-76.6).
NEWGENIVF GROUP LTD-A (NIVF) has a market capitalization of 1.41M USD. This makes NIVF a Nano Cap stock.
ChartMill assigns a fundamental rating of 1 / 10 to NIVF. NIVF may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NIVF reported a non-GAAP Earnings per Share(EPS) of -76.6. The EPS decreased by -486.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.22% | ||
| ROE | -4.4% | ||
| Debt/Equity | 0.1 |
null analysts have analysed NIVF and the average price target is 15.3 USD. This implies a price increase of 1913.16% is expected in the next year compared to the current price of 0.76.